| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 214.80 | 11767 |
| Intrinsic value (DCF) | 1.18 | -35 |
| Graham-Dodd Method | n/a | |
| Graham Formula | 41.58 | 2197 |
Daré Bioscience, Inc. (NASDAQ: DARE) is a clinical-stage biopharmaceutical company focused on advancing innovative therapies for women's health. Headquartered in San Diego, California, the company specializes in developing treatments for contraception, fertility, and sexual and vaginal health. Its flagship product, XACIATO, is a single-dose vaginal gel for bacterial vaginosis, currently marketed in partnership with Organon. Daré's pipeline includes Ovaprene, a hormone-free monthly contraceptive, and Sildenafil Cream for female sexual arousal disorder, both in advanced clinical trials. Additionally, the company is developing hormone therapy solutions like DARE-HRT1 for vasomotor symptoms and DARE-VVA1 for vulvar and vaginal atrophy in breast cancer patients. With a strong focus on unmet medical needs in women's health, Daré leverages novel drug delivery technologies, including intravaginal rings and topical formulations. The company operates in the high-growth biotechnology sector, targeting a market with increasing demand for specialized women's healthcare solutions.
Daré Bioscience presents a high-risk, high-reward investment opportunity in the underserved women's health sector. The company's clinical-stage pipeline addresses significant unmet needs, with potential catalysts including Phase 3 data for Ovaprene and commercialization progress for XACIATO. However, as a pre-revenue biotech (2023 revenue: $9,784), Daré carries substantial risk—negative EPS (-$0.48), cash burn, and dependence on successful clinical trials and partnerships. The $25.7M market cap reflects these risks but could offer upside if key pipeline assets demonstrate efficacy. Investors should monitor upcoming clinical milestones, partnership developments (particularly with Organon), and cash runway ($15.7M cash as of last report). The 1.2 beta indicates higher volatility than the market, typical for developmental biotech stocks.
Daré Bioscience competes in the niche but growing women's health biopharmaceutical market, differentiating itself through specialized drug delivery platforms and a focused pipeline. The company's competitive advantage lies in its targeted approach to under-addressed conditions like hormone-free contraception (Ovaprene) and topical sexual dysfunction treatments (Sildenafil Cream), areas with limited competition. Its partnership with Organon for XACIATO provides commercialization expertise it lacks as a small biotech. However, Daré faces significant challenges competing with larger women's health players like Agile Therapeutics (hormonal contraceptives) and TherapeuticsMD (menopausal therapies), which have greater resources and established products. The intravaginal ring technology (DARE-HRT1, DARE-FRT1) could be disruptive if proven effective, but faces competition from existing hormone therapies. Daré's preclinical male contraceptive (DARE-RH1) is highly innovative but scientifically risky. The company's modest cash position ($15.7M) limits its ability to independently advance multiple pipeline assets, making strategic partnerships critical. Success hinges on demonstrating superior efficacy/safety versus existing treatments in late-stage trials and securing additional funding or partnership deals to sustain operations.